Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns

Raising US corporate taxes would reduce corporate investment in the US and particularly impact jobs, Johnson & Johnson chief financial officer Joseph Wolk cautioned during the company's first quarter sales and earnings call on 20 April.

Tax Sales & Earnings Policy & Regulation

Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.

Gene Therapy Deals Business Strategies

Novartis Q1 Preview: Profits Still Under Pressure From Lockdown

The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular. 

Sales & Earnings Strategy Commercial

Scrip Podcast

Listen to Scrip podcasts for our perspectives on biopharma R&D, deal-making, product strategies and other key commercial topics.
 

 

Click to read Six Themes That Will Shape Biopharma In Transformational 2021

Key Predictions From Industry Leaders

 

 

 


Recent Tweets from Scrip


 

Infographics

Pandemic Perspectives: China Vaccine Diplomacy - A World On Shots

Over 50 countries around the world are now receiving COVID-19 vaccine deliveries from China, totaling 3.3 million doses and counting so far. This Scrip infographic shows their locations, quantity of supplies and the developers involved.

2020 Deal-Making Snapshot: A Busy Year For Bolt-Ons

Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.

Predicting Success: The Easiest, And Hardest Routes To Market

A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.

Commercial Explore this Topic

Set Alert for Commercial

Sanofi Q1 Preview: Building The Pipeline, Improving Business Efficiencies

Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.

Sales & Earnings Business Strategies

J&J, Hopeful On COVID-19 Vaccine Outlook, Looks To Restore Public Confidence

The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.

Coronavirus COVID-19 Vaccines

Swiss Biotechs May Get SPAC Listing Option Soon

Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.

Switzerland Companies

Focus On J&J, Pfizer COVID-19 Vaccine Pricing As India Permits Private Sales

Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.

India Coronavirus COVID-19

AZ And J&J’s Problems Fuel Demand For Pfizer and Moderna COVID-19 Vaccines

Pfizer/BioNTech is emerging as the EU’s partner of choice for COVID-19 vaccines, but others could also benefit.

Commercial Companies

A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen

Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.

Intellectual Property Legal Issues
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

China Cancer Drug Misuse In Spotlight After Shocking Whistleblower Tales

Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.

China ImmunoOncology

Swiss Biotechs May Get SPAC Listing Option Soon

Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.

Switzerland Companies

A Whole New Year For Pharma: Macro Pressures Mount Heading Into Q1 Reporting

First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.

Sales & Earnings FDA
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Budesonide Shows COVID-19 Promise: Should It Be Evaluated In India?

UK studies indicate the potential of inhaled budesonide in improving COVID-19 recovery time in specific groups, with some leading Indian physicians suggesting that the widely available asthma/COPD therapy should be selectively evaluated in the Indian context as well.

Coronavirus COVID-19 Clinical Trials

Aelix Therapeutics' Multi-Vector Therapeutic HIV Vaccine Could Be Backbone Of Combination Strategy

Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.

Infectious Diseases Clinical Trials

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

Research & Development Vaccines
See All
UsernamePublicRestriction

Register